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Soft tissue rheumatism includes a wide spectrum of common lesions of the tendons, enthesis,
tendon sheaths, bursae, ligaments and fasciae as well as nerve compression syndromes. Studies
on the pathogenesis of these lesions do not support a major role for inflammation, thus
questioning the rationale for glucocorticoid injections. This chapter reviews current indications
for local glucocorticoid injections and available evidence on its efficacy, as well as contra-
indications and potential risks. Randomised controlled studies of good methodological quality are
rare and there is limited scientific evidence to support the superiority of glucocorticoid injections
over alternative treatments.
The basic principles of the glucocorticoid injection method are outlined, together with a
description of the practical procedure for the more common conditions.
Key words: soft tissue rheumatism; treatment; glucocorticoid injection.
Periarticular soft tissue rheumatic disorders include a wide spectrum of localised
lesions of the tendons, enthesis, tendon sheaths, bursae, ligaments and fasciae as well as
nerve compression syndromes. They are extremely common in daily practice and
result in significant morbidity and socioeconomic impact. These aspects, together with
their tendency to chronicity and recurrence, make the treatment of these conditions an
important health care issue.
Local injection of corticoglucocorticoid agents is commonly used for this purpose.
This is usually perceived as a simple, safe and effective procedure. In this chapter we will
explore the rationale and, in particular, the evidence base for their use. Basic principles
of the glucocorticoid injection method are outlined and the most common procedures
are described.doi:10.1016/j.berh.2005.01.003
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Clinically, soft tissue lesions are commonly classified as acute (up to 2 weeks in
duration), subacute (2–4 weeks) and chronic (over 6 weeks). Early intervention in soft
tissue lesions is based on patient education, aimed at resolving the injury and preventing
chronicity and recurrence.1–3 Proposed measures include correction of aggravating
factors, relative rest and appropriate exercise. Initial control of pain may be achieved
through analgesics and non-glucocorticoidal anti-inflammatory drugs (NSAIDS), ice,
ultrasound and transcutaneous electrical nerve stimulation, although evidence to
support these approaches is scarce.4
Soft tissue injections with glucocorticoids are commonly reserved for chronic cases,
after an adequate trial of other conservative measures for at least 2 months has failed.1
Local anaesthetic is frequently mixed with the glucocorticoid for soft tissue injections,
with several potential advantages: reduction of discomfort during the procedure,
confirmation of the diagnosis by the immediate abolition of pain and an increased
injection volume, where needed for wider dispersion.5 Occasionally, as in trigger
points, local anaesthetic may be injected alone, without glucocorticoid.6 The main soft
tissue conditions usually considered amenable to local glucocorticoid injection are
listed in Table 1.
The rationale for the use of corticoglucocorticoids in these disorders presumes that
there is an inflammatory process and that the control of inflammation will lead to the
resolution or improvement of the disorder. However, evidence from histopathological,
biochemical and molecular studies does not support a major role of inflammation in
these conditions.1,7,8
Painful tendon lesions are usually named ‘tendinitis’, a term that implies an
inflammatory process. In most cases, this is thought to be the result of repetitive
microtrauma causing repeated microstrain below the failure threshold of the tendon.4
Such continued tendon overload leads to injury to collagen fibrils, matrix and
microvasculature, accompanied by inflammation of the paratenon, which becomes
fibrotic and thickened. The role and relevance of inflammation at the early stage is not
clear.7 It is conceivable that the degree of inflammation may vary with time, justifying
differences in the rhythm of pain and in the response to glucocorticoid injection.
However, this hypothesis remains to be proven. In the final stages, pathology consists
mostly of tendon degeneration or ‘tendinosis’, without signs of intratendinous
inflammation.7–10 The entire tendon architecture is deranged, including collagen,
tenocytes and extracellular matrix, with associated degenerative and reparativeTable 1. Common indications for soft tissue glucocorticoid injection.
Anatomical region Soft tissue disorder
Shoulder Rotator cuff tendinitis; subacromial bursitis; bicipital tenosynovitis
Elbow Olecranon bursitis; lateral and medial epicondylitis
Wrist and hand Carpal tunnel syndrome; De Quervain’s tenosynovitis; extensor and flexor
tenosynovitis; trigger fingers
Hip Trochanteric bursitis; iliopsoas bursitis; ischiogluteal bursitis; addutor
tendinitis; meralgia paraesthetica
Knee Pes anserinus lesions and anserine bursitis; patellar tendinitis
Ankle and foot Tarsal tunnel syndrome; posterior tibialis tenosynovitis; plantar fasciitis;
Morton’s interdigital neuroma
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for describing these conditions.EFFICACY
Although soft tissue injections are very popular among rheumatologists and have stood
the ‘proof of time,’ there is a remarkable paucity of controlled data to support their
efficacy. Randomised controlled trials are scarce and their interpretation is frequently
hindered by methodological issues, such as poor definition of cases, inclusion of
heterogeneous study populations, small sample sizes, unsuitable outcome measures,
short term follow up, inadequate blinding and lack of true placebo.1,4,11
Evaluation of efficacy may be hampered by unreliability of diagnosis and accuracy of
injection. Even in a specialist’s hands, up to 70% of periarticular injections may be
misplaced.12 Increasing use of ultrasonography and magnetic resonance imaging for
diagnosis and ultrasound-guided injection may improve this.13 Placement of
glucocorticoids under ultrasound guidance is, of course, much more precise than
blind injections.14,15 It is intuitive to expect ultrasound-guided injections to be more
effective and safe. However, demonstration of this potential advantage by adequate
studies is still scarce.16 The current scientific evidence on the efficacy of blind soft tissue
glucocorticoid injection is reviewed below.
Rotator cuff tendinopathy
Buchbinder et al in a Cochrane systematic review4, identified 10 controlled trials
comparing glucocorticoid injection for rotator cuff tendinopathy with placebo and
other active interventions, including NSAIDS, physiotherapy and acupuncture. Four
out of seven placebo-controlled trials17–23 reported efficacy of glucocorticoid
injections. Results from two of these trials could be pooled, showing a small benefit
of injection over placebo at 4 weeks, with regard to pain and function. Pooled results of
three trials comparing subacromial glucocorticoid injection to oral NSAID17,20,24
showed no benefit of one treatment over the other at 4 or 6 weeks of follow-up. Based
upon these findings, there is little evidence to either support or refute a superior
efficacy of glucocorticoid injections for rotator cuff tendinopathy.4
Lateral epicondylitis
Assendelft et al performed a systematic review of randomised controlled trials on the
effectiveness of glucocorticoid injection for lateral epicondylitis.25 They analysed 12
trials, including ten placebo-controlled studies, but the overall methodological quality
was poor to moderate. Pooled results from nine trials favoured glucocorticoid injection
in the short term (up to 6 weeks) but showed no significant differences in long term
effects. In a randomised controlled trial carried out by Hay et al comparing
glucocorticoid injection to NSAIDs and analgesics26, outcome was favourable to
injection after 4 weeks, with no difference between groups at 1 year.
Olecranon bursitis
In a retrospective study by Weinstein et al27, 47 patients with traumatic olecranon
bursitis were treated by bursal aspiration with or without intrabursal glucocorticoid
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submitted to glucocorticoid injection. However, injected patients suffered compli-
cations, such as infection (three cases in 25 patients) and skin atrophy (five cases in 25
patients), which were not seen in those submitted to aspiration alone.De Quervain’s tenosynovitis
Anderson et al in a non-controlled study28, submitted 56 cases of De Quervain’s
tenosynovitis to glucocorticoid injections and assessed effectiveness by follow-up for
an average of 4.2 years. At 6 weeks post-injection, 81 and 13% of patients experienced
complete or partial clinical response, respectively, while 58% maintained complete
resolution for the duration of follow-up and 27% needed reinjections for recurrence.
Ultimately, 90% experienced a good response to injection and only 10% required
surgery. Other short-term and retrospective studies also report benefit. We are not
aware of any controlled prospective trials.Trigger finger
In a double blind, placebo-controlled trial, Lambert et al29 compared glucocorticoid
injection plus local anaesthetic to anaesthetic alone in 41 patients with trigger finger.
Significant improvement was experienced by 60% of the glucocorticoid group,
compared with 16% of controls at 1 month of follow-up. A similar trial involving 24
patients, also showed benefit of glucocorticoid injection at 3 weeks’ follow-up.30
Anderson and Kaye, in a non-controlled study31, treated 77 trigger fingers in 58
patients by glucocorticoid injection and followed them up for an average of 4.6 years. In
the long term, a single injection was successful in 61% of the cases and a further 27% had
recurrences that responded well to multiple injections, while 12% were referred for
surgery.Carpal tunnel syndrome
Most studies on local glucocorticoid injection for carpal tunnel syndrome (CTS) are
either retrospective or non-randomised.11 Dammers et al32 compared glucocorticoid
injection in 30 patients with placebo injection in another 30, following a randomised
controlled design. The results demonstrated significant improvement in the
glucocorticoid versus placebo group, at 1 month post-injection. A longer duration of
relief, up to 1 year, is suggested by the open extension of this study and other non-
controlled trials. Celiker et al33 performed an unblinded, randomised controlled trial
comparing local glucocorticoid injection versus oral NSAID and wrist splinting in 23
patients with CTS. The results demonstrated clinical improvement in both treatment
groups at 8 weeks of follow-up, with no superiority for one treatment over the other.
Subjects with milder CTS may be more responsive to glucocorticoid injection than
those with a more severe condition, according to one prospective trial.34Trochanteric bursitis
In an open study of glucocorticoid injection for trochanteric bursitis35, 77 and 61% of
75 patients reported improvement at 1 and 26 weeks of follow-up, respectively.
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In a double-blind randomised controlled trial, DaCruz et al36 found no benefit of
glucocorticoid plus anaesthetic injection over anaesthetic alone in 28 subjects.
In conclusion, the efficacy of local corticoglucocorticoid injections in the treatment
of periarticular soft tissue lesions has been the object of a limited number of trials,
frequently affected by methodological limitations. Overall, there is some evidence that
glucocorticoid injections may be faster in relieving symptoms than alternative
treatments for some conditions. There is no evidence that this benefit may be long-
lasting for the majority of these disorders. There is a clear need for further trials of
good methodological quality to settle this question.CONTRAINDICATIONS AND RISKS
There are few contraindications to soft tissue corticoglucocorticoid injections, as
shown in Table 2. In addition, they are very safe, as long as the indications,
contraindications and technical recommendations are respected. Potential adverse
effects are listed in Table 3. Their actual incidence is unknown.
Patients should always be asked about previous allergic reactions to local
anaesthetics and glucocorticoids. Moderate pain at the injection site is common. An
inflammatory flare, characterised by aggravation of pain, swelling and redness for up to
48 hours following the injection occurs occasionally and may represent a reaction to
glucocorticoids crystals.37 A reaction persisting beyond 48 hours requires evaluation
for possible infection and other complications. Risk of infection is estimated to be very
low38 when using sterile ‘no-touch’ techniques.
Misplaced injections may result in tendon rupture and nerve damage. For this
reason, injections should not be performed inside the tendon, i.e. against resistance.
Loading the tendon after infiltration and multiple glucocorticoid injections may also
predispose to rupture. The Achilles tendon seems especially prone to such accidents. If
dysesthesiae arises on attempted injection of a nerve tract, for example in the carpal
tunnel, the needle should be repositioned, to avoid nerve damage.
Subcutaneous tissue atrophy and skin depigmentation are more frequently reported
following superficial glucocorticoid injections, as for subcutaneous bursae and De
Quervain’s tenosynovitis. These may be more likely if long-acting glucocorticoids, such
as triamcinolone hexacetonide, are given.
Absorption of glucocorticoids after local injection may be sufficient to produce
systemic effects, such as temporary suppression of the hypothalamic-pituitary-adrenal
axis. However, systemic side effects are rare.Table 2. Contraindications to soft tissue glucocorticoid injections.
Absolute Infection in locality
Serious allergy to local anaesthetics or glucocorticoids
Relative Anticoagulation or bleeding diathesis
Systemic infection
Table 3. Adverse reactions after soft tissue glucocorticoid injection.
Immediate Pain at the injection site
Inflammatory flare reaction
Ecchymosis at the injection site
Infection
Vasovagal reaction
Anaphylaxis
Late Subcutaneous tissue atrophy
Skin depigmentation
Tendon rupture
Nerve damage
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Published recommendations for soft tissue injections are based on personal experience
and anecdote more than on evidence. Even for conditions that have been more
extensively studied, such as tennis elbow, a systematic review of 12 randomised
controlled trials failed to reach any conclusions with respect to the most suitable
glucocorticoid, the most adequate dose, injection volume or interval.25 Common
practice is remarkably variable between centres and practitioners with respect to
almost all aspects of the procedures: environment, antiseptic care, use and volume of
anaesthetic, type and dose of glucocorticoid, rest after injection, etc.39
The technical recommendations presented here have the same limitations: they are
based on our personal experience, informed by the published recommendations of
others40–45 and only occasionally supported by hard evidence, in the rare instances
where this is available.Preparation
Local injection should be based as much as possible on a clear diagnosis and careful
consideration of the risks, benefits and alternative approaches. The patient should be
asked for informed consent and accept the post-injection recommendations. The
practitioner should have good knowledge of the local anatomy, indications and
contraindications and technical details of the procedure. Enough experience should be
gained before independent performance.Materials† Carefully wash your hands before starting preparation of drugs
† Use short or medium-acting glucocorticoid preparations for most cases
(methylprednisolone acetate will usually be a good choice)
† A suitable volume of local anaesthetic (e.g. lignocaine 1%) may be mixed in certain
conditions
† Make sure that the anaesthethic solution is clear and devoid of any debris before
collecting it in the syringe
† Always use sterile disposable needles and syringes
† Select the smallest possible diameter of needle that can reach the lesion
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Use a no-touch technique: swab your hands and the patient’s skin with iodine or 70%
ethanol. Do not touch the site of injection or the needle after swabbingTechnique† Patient and practitioner should be in a comfortable position
† Always try to support the hand holding the syringe, so that movements are finely
controlled.
† Mark the site of injection with pencil or a pressure mark
† Surface anaesthesia may be necessary for sensitive patients
† Cross the skin quickly as this is the most sensitive area
† Advance until the tip of the needle is inside the lesion
† Always draw back on the syringe before injecting, to make sure that the needle is not
in a vascular structure
† Cover the periphery of a tendon using a fan technique with half-withdrawals and
reinsertions: inject a small volume, redraw the needle towards the skin and
reintroduce it in another direction. Inject again and repeat these steps until the
lesion is covered.
Please note that injections should be done into the periphery of tendons and not in
their interior. Advance the tip of the needle into the tendon and test the resistance to
the embolus: it should be high if the tip of the needle is inside the tendon. Redraw the
needle slowly while pressing the embolus. When resistance goes down, the tip of the
needle should be in the periphery of the tendon: that is where the glucocorticoid
should be placed.Post-injection care† Cover the injection site with a sterile strap
† Ask the patient to gently move the area in order to spread the fluid.
† Ask the patient to contact you in case of any suggestion of infection or other
significant adverse event
Advice regarding rest after the injection is variable. Absolute rest of the injected area
for 24 hours and limited use for 2–4 weeks is a common recommendation that we have
followed with satisfactory results. Several authors suggest that local injections should
not be repeated before 6 weeks and that no more than three injections should be done
on the same site. Such recommendations seem based on fear of tendon rupture, but we
are unaware of any sound evidence to support their value.Choice of glucocorticoid preparations
Table 4 shows some characteristics of the most common injectable preparations of
glucocorticoids. Low solubility is associated with longer duration of action. Long-acting
fluorinated glucocorticoids, namely triamcinolone hexacetonide, which are frequently
preferred for intra-articular injections are considered by some authors to be
inadequate for periarticular injections, due to a higher risk of atrophy in the
Table 4. Common injectable glucocorticoid preparations.
Potency Concentration (mg/ml) Solubility (%wt/vol)
Hydrocortisone acetate 1 25 0.002
Prednisolone acetate 4 25 0.001
Methylprednisolone acetate 5 20,40,80 0.001
Triamcinolone acetonide* 5 10,40 0.004
Betametasone sodium
posphate/acetate*
25 6 NA
Dexamethasone phosphate* 25 4 0.01
Triamcinolone hexacetonide* 5 20 0.0002
Source: adapted from Gray et al 1981.38 *Fluorinated compounds. NA, not applicable.
510 L. P. B. S. Ineˆs and J. A. P. da Silvasurrounding tissues.40,41 Others, however, recommend triamcinolone for soft tissue
injections.46
Methylprednilone acetate (MPA) is the most commonly recommended glucocorti-
coid for soft tissue injections and will be taken as the reference standard in this chapter.
Needle placement and ultrasound
Despite the fact that rheumatologists feel very confident and satisfied with their own
injection practice and results, controlled studies show that, even in the hands of
specialists, glucocorticoid is frequently placed outside the target area. In the study
carried out by Eustace et al12 regarding shoulder injections, only 29% of the subacromial
and 42% of the intra-articular injections were correctly placed by experienced
practitioners. Similar results were found with regard to De Quervain’s tenosynovitis.47
These studies also demonstrated that the outcome was closely related to the accuracy
of the injection.
Such observations underline the need for careful consideration of the technique, but
raise considerable uncertainty in the face of the numerous variations that can be found
in published recommendations and, even more, in clinical practice. The suggestions
given below reflect our preferences and current practice.SITE-SPECIFIC TECHNIQUES
Subacromial space
The following techniques may be used to treat rotator cuff tendinopathy and
subacromial bursitis.
Material† 5–10 ml syringe
† 40!0.7 mm (22G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (3–4 ml)
Figure 1. Injection of the subacromial space: posterolateral approach.
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Use the posterior tip of the acromion as an anatomical reference. Insert the needle into
the space between the acromion and the humeral head (Figure 1) and drive it in an
anteriorly-directed course toward the coracoid process. Inject under the acromion.
Resistance to drug delivery should be minimal.Lateral approach
Palpate the gap between the acromion and the head of the humerus on the tip of
the shoulder. Insert the needle into this space (Figure 2) aiming it slightly upwards
and inject under the acromion. There should be little or no resistance to the
plunger.Anterior approach
This is a personal adaptation with good, although anecdotal, results. The shoulder is
kept in forced internal rotation (hand behind the back). The greater tuberosity of the
humerus with the supraspinatus tendon can now be felt anteriorly to the acromion. The
subacromial bursa covers these structures. The most tender point is identified and
marked. Enter the skin perpendicularly to the surface (Figure 3) and inject several spots
in the periphery of the tendon.
Figure 3. Injection of the subacromial space: anterior approach.
Figure 2. Injection of the subacromial space: lateral approach.
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Material† 2–5 ml syringe
† 40!0.7 mm (22G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (2 ml)
The biceps tendon can be easily palpated in the anterior aspect of the shoulder, in its
groove. Identify the most tender spot, enter the skin perpendicularly to the surface and
progress with the needle until the bone (Figure 4). Inject about 1 ml of the mixture
following the general recommendations. Redraw the needle about 2 cm and redirect it
to the tendon sheath about 2 cm above the previous spot and inject again. Repeat the
procedure 2 cm below the original spot.Figure 4. Injection of the biceps tendon sheath.
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Material† 2 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 20–40 mg MPA (0.5–1 ml)
The elbow is semiflexed and supported. The needle is inserted into the site of
maximal tenderness until it reaches bone (Figure 5). Slightly withdraw the needle and
infiltrate both deeply and superficially using a fan technique as suggested in the general
recommendations. Warn the patient of probable exacerbation of pain for 24–48 hours.
Be aware of the ulnar nerve when injecting the medial epicondyle. Some authors
recommend that, contrary to the general recommendation, glucocorticoids should, in
these lesions, be placed inside the tendons, as close as possible to their insertions on
bone. This requires the use of a small volume of glucocorticoid, without anaesthetic,
which is injected under pressure.Carpal tunnel
Material† 2 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 20–40 mg MPA (0.5–1 ml)Figure 5. Injection of the lateral epicondyle.
Figure 6. Injection of the carpal tunnel.
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resistance. Enter the skin medially to this tendon at the distal palmar crease in the wrist.
Keep the syringe at an angle of 458 to the forearm and inject the glucocorticoid about
1–2 cm below the skin (Figure 6). There should be no resistance to injection and no
pain or paraesthesia in the median nerve territory.
De Quervain’s tenosynovitis
Material† 2 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 20–40 mg MPA (0.5–1 ml)
† 1% lignocaine (1 ml)
Identify the site of maximal tenderness on the tendons sheaths. Keeping the thumb
under resisted abduction, enter the skin from the hand at an angle of about 308, aligned
with the tendon and aiming the tip of the needle towards the peritendinous space
(Figure 7). Inject at different spots around the tendon, avoiding any resistance.
Flexor tendon sheaths
Material† 2 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 20 mg MPA (0.5–1 ml)
Figure 7. Injection of de Quervain’s tenosynovitis.
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sheaths on the palmar aspect of the metacarpal heads or proximal phalanx (usually
proximally to the metacarpal crease). Enter the skin from the fingers at an angle of
about 458, aligned with the tendon and aiming the tip of the needle to the peritendinous
space (Figure 8). Check that the needle is touching the tendon: passive motion of the
finger will induce movement in the needle. Redraw the needle slightly until resistance
against injection is lost: place the glucocorticoid as close to the tendon as possible.Greater trochanter
Material† 10 ml syringe
† 50!0.8 mm (21 G) gauge needles
† 40–80 mg MPA (1–2 ml)
† 1% lignocaine (3–5 ml)
In some patients tenderness is limited to a small area on the lateral aspect of the
greater trochanter, suggesting trochanteric bursitis. More frequently, however, in our
experience, maximal tenderness is found along the muscle insertions in the superior
and posterior borders of the great trochanter, requiring larger injection volumes and,
frequently, more than one injection site. The patient should lie on the opposite side to
the lesion. Carefully identify the sites of maximal tenderness and mark points on the
skin that will allow best access to them in a fan-like technique. Enter the skin and
advance the needle until it reaches bone (Figure 9). Redraw the needle slightly and inject
Figure 8. Injection of flexor tendon sheath.
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a fan technique.Adductor tendinopathy
Material† 5 ml syringe
† 50!0.8 mm (21 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml)
Carefuly identify the site of maximal pain in the insertion of the adductors close to
the pubic symphysis. Inject around the tendon.Ischiogluteal bursitis
Material† 5 ml syringe
† 50!0.8 mm (21 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml)
Locate the site of maximum tenderness while the patient is lying on his back or side.
Inject into and around this area.
Figure 9. Injection of the greater trochanter area.
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Material† 5 ml syringe
† 50!0.8 mm (21 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml)
The injection should be made at one of two sites: either around 1 cm below and
medially to the anterior superior iliac crest or 10 cm below this point. We usually select
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inserted perpendicular to the skin and the injection performed at about 2 cm of depth.Pes anserinus
Material† 10 ml syringe
† 50!0.8 mm (21G) gauge needles
† 40–80 mg MPA (1–2 ml)
† 1% lignocaine (3–5 ml)
In our experience, pain in the medial aspect of the knee is frequently related to
marked tenderness in the tendons of the isquio-tibial muscles at the level of the medial
femur condyle or just above it. Injection into these tender sites is frequently rewarding
for the patient and the physician. The patient should lie on the side of the lesion, with
the affected knee slightly flexed. Carefully identify the sites of maximal tenderness and
mark points in the skin that will allow best access to them in a fan-like technique
(Figure 10). Enter the skin and advance the needle until it reaches bone. Redraw the
needle slightly and inject a small volume. Address the painful structures using a fan
technique.
Occasionally pain is confined to a limited area in the anteromedial aspect of the
proximal tibia, suggesting true anserine bursitis. The technique for this follows the same
principles. Injection volumes are accordingly smaller.Figure 10. Injection of the pes anserinus.
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Material† 5 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–3 ml)
Tenderness in the illiotibial band syndrome is usually located over the lateral condyle
where the band slips backwards and forwards as the knee flexes and extends. The
injection should be directed to the site of maximum tenderness. Occasionally there
may be swelling due to bursitis under the band, which should also be injected.
Achilles bursitis
Material† 5 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1 ml)
The needle is directed towards the bursa lying anteriorly or posteriorly to the
Achilles tendon. Injection into the tendon is strongly contra-indicated due to a high risk
of tendon rupture.
Enter the skin on the lateral side of the heel, just above the top of the calcaneum.
Direct the needle medially to the pre-achillean bursa or downward to the retro-
achillean bursa, which lies just beneath the skin (Figure 11). Never inject against
resistance.
Tarsal tunnel
Material† 5 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1 ml)
Inject under the flexor retinaculum, between the calcaneus and the medial malleolus.
Plantar fasciitis
Material† 5 ml syringe
† 40!0.7 mm (22G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml)
Figure 11. Injection of Achilles bursitis.
Soft tissue injections 521Locate the site of maximum tenderness on the plantar surface of the heel. The
injection should be placed as close as possible to the insertion of the fascia in the bone.
This can be addressed perpendicularly to the plantar skin (25G needle) or via the
medial side of the heel (22G needle: Figure 12), so that the injection site lies beneath the
tender spot.Tenosynovitis of the posterior tibialis
Material† 5 ml syringe
† 20!0.5 mm (25 G) gauge needles
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml)
Figure 12. Injection of plantar fasciitis.
Figure 13. Injection of tenosynovitis of the posterior tibial tendon.
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Soft tissue injections 523Palpate the tender tendon sheath posteriorly and distally to the medial malleolus.
The needle is inserted towards the leg, on a tangent to the bone (Figure 13). The
injection is placed about 1 cm beneath the skin. We find this injection difficult to place
precisely and tend to ask for ultrasound guidance.
Morton metatarsalgia
Material† 5 ml syringe
† 20!0.5 mm (25 G) gauge needlesFigure 14. Injection of tender and trigger points.
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† 1% lignocaine (1–2 ml)
The usual recommendations suggest that the injection should be performed in the
intermetatarsal space around the site of maximum tenderness.Tender and trigger points
Material† 5 ml syringe
† 40 mg MPA (1 ml)
† 1% lignocaine (1–2 ml) or dry needling
Tender or trigger points should be carefully identified before insertion of the needle.
Ideally a taut band is clearly located and secured between the index and middle finger of
one hand. The needle is inserted at an angle of about 458 to the skin, parallel to the
muscle fibres (Figure 14). The injection is placed inside the taut band, using a fan
technique if needed.SUMMARY
Soft tissue rheumatic disorders are extremely common and result in significant
morbidity, loss of productivity and socioeconomic impact.
Early intervention is aimed at resolving the injury and preventing chronicity and
recurrence. Soft tissue glucocorticoid injections are commonly reserved for chronic
cases. Evidence from histopathological, biochemical and molecular studies do not
support a major role for inflammation in soft tissue disorders, undermining the
rationale for the use of glucocorticoid injections in these conditions. Although
glucocorticoid injections are associated with relief in the short term, evidence to either
support or refute their superiority over alternative treatments is scarce, particularly in
the long-term. This may reflect the true efficacy of injections or may be due to the lack
of adequate studies. There is a clear need for further trials of good methodological
quality to settle this question.
The clinical decision to perform a local glucocorticoid injection should be based on a
clear diagnosis and careful consideration of the risks, benefits and alternative
approaches. The practitioner should have good knowledge of the local anatomy and
technical experience of the procedure. Provided that technical recommendations are
respected, glucocorticoid injections have few contraindications and are safe procedures
.Practice points
† scientific evidence does not support a major role for inflammation in soft tissue
rheumatism and hence the rationale for the use of glucocorticoid injections for
its treatment
† studies on the efficacy of glucocorticoid injections are limited in number and
quality
† overall, local soft tissue injections are associated with short-term benefit but
uncertain long-term results
† local injection should be based, as much as possible, on a clear diagnosis and
careful consideration of the risks, benefits and alternative approaches
† soft tissue glucocorticoid injections are usually reserved for chronic cases, after
the failure of other conservative measures.
† glucocorticoid injections have few contraindications and are very safe, provided
that technical recommendations are respected.
Research agenda
† progress in this area will demand considerable refinement in the methodology
of clinical trials, including a careful definition of cases and endpoints
† further controlled studies of good methodological quality are needed to
establish the true efficacy of glucocorticoid injections, especially in the longer
term
† studies designed to evaluate the relevance of glucocorticoid type and dose,
post-injection rest and other technical details should be encouraged
† research is needed to establish the value of MRI and ultrasonography as means
of improving injection efficacy, through improved diagnosis and injection
guidance
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